Given the rising incidence of NASH, for which T2D is a significant risk factor, and the beneficial effects we observe with respect to adiposity and inflammatory cell infiltration in adipose tissue, evaluation of Cmpd 1 or related PKC inhibitors in a pre-clinical NASH setting, and for obesity more generally, may be warranted. The gene discussed is PRRT2; the disease is metabolic dysfunction-associated steatohepatitis.